Korea United Pharm Boosts Shareholder Returns with KRW 610 Dividend and 2.6% Share Cancellation, but Governance Gaps Remain
For FY2025, declared a cash dividend of KRW 610 per share (yield 3.1%), up 35.6% from KRW 450 last year; total payout KRW 9.68B (payout ratio 25.26%).
In March 2026, cancelled 423,047 common shares (approx. 2.6%) to strengthen shareholder returns.
Maintains 30 consecutive years of cash dividends and plans to continue expanding dividends.
Adopted e-voting to improve shareholder rights, but only 5 out of 15 core governance indicators met (33%), including failure to provide 4-week notice before AGM and lack of CEO succession policy.
Audit committee consists entirely of independent directors ensuring independence, but no dedicated internal audit department exists.
[AI Comprehensive Analysis]Korea United Pharm actively returns value via buybacks and dividends, but governance improvements are urgent. To enhance long-term corporate value, it should strengthen CEO succession planning and internal control systems.